Success Metrics

Completion Rate
0%(0/2)
Active Trials
2(40%)
Terminated
2(40%)

Phase Distribution

Ph phase_3
4
80%
Ph phase_2
1
20%

Phase Distribution

0

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
4(80.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(3)
Terminated(2)

Detailed Status

Terminated2
Recruiting1
Active, not recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (20.0%)
Phase 34 (80.0%)

Trials by Status

recruiting120%
active_not_recruiting120%
not_yet_recruiting120%
terminated240%

Recent Activity

2 active trials
Showing 5 of 5
not_yet_recruitingphase_3

Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral Anticoagulation

NCT07739888
recruitingphase_3

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

NCT05712200
terminatedphase_3

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

NCT05171075
terminatedphase_3

A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

NCT05171049
active_not_recruitingphase_2

Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation

NCT04755283

Clinical Trials (5)

Showing 5 of 5 trials
NCT07739888Phase 3

Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral Anticoagulation

Not Yet Recruiting
NCT05712200Phase 3

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

Recruiting
NCT05171075Phase 3

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

Terminated
NCT05171049Phase 3

A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

Terminated
NCT04755283Phase 2

Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation

Active Not Recruiting

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5